Dongkook Pharmaceutical Launches Patented Oral Probiotic "Myfit B Oral Probiotic"

Dongkook Pharmaceutical announced on the 12th that it has launched its patented oral probiotic product, "Myfit B Oral Probiotic."

Myfit B Oral Probiotic Product by Dongkook Pharmaceutical. Dongkook Pharmaceutical

"Myfit B Oral Probiotic" is characterized by the use of patented strains isolated from the gingiva (gums) of healthy Korean adults. It combines two strains: Streptococcus salivarius G7 and Lactobacillus plantarum GSPE05.

The new product contains 3.6 billion CFU (colony-forming units) of live probiotics, formulated to maintain a guaranteed count of 100 million CFU. Notably, it contains 0% sugar and 400 mg of xylitol, making it suitable for consumption even after brushing teeth or before bedtime without concern. Additionally, it comes in a chewable tablet form that can be chewed or dissolved without water, offering convenience and a refreshing mint flavor for a pleasant mouthfeel.

The product uses a probiotic-specific container designed for strong sealing and triple protection, which blocks out external moisture, oxygen, and light. Its special design allows the probiotics to remain viable even at room temperature. It is manufactured in a HACCP-certified facility that meets the food safety management standards of the Ministry of Food and Drug Safety, ensuring strict quality control throughout the production process.

A marketing representative from Dongkook Pharmaceutical commented, "Since the oral cavity is the second most populated site for microorganisms after the gut in our body, we focused on managing the oral environment to support the growth of beneficial bacteria, which led to the launch of ‘Myfit B Oral Probiotic.’ We hope that by taking one tablet per day—whether you need oral care at any moment, wish to take oral probiotics before bedtime, or want a fresh mouth in the morning—consumers can maintain optimal oral health in various situations."

This content was produced with the assistance of AI translation services.